First a bit of background on the different measures of pandemic preparedness 3/
Following the 2014–16 Ebola epidemic in West Africa, @WHO & partners developed Joint External Evaluation (JEE) process to monitor countries’ adoption and implementation of the core capacities under the International Health Regulations 4/
More than one hundred nations have undertaken voluntary Joint External Evaluations
This super helpful @ResolveTSL tool combines the results into a single score for each country, based average score of 19 preparedness areas measured by JEE 5/ preventepidemics.org/map/
Another metric, the 2019 Global Health Security (GHS) Index go beyond JEE.
It's a comprehensive assessment & benchmarking tool that measures country capacity to rapidly respond to & mitigate spread of an epidemic 6/ ghsindex.org/about/
Universal health coverage (UHC), a measure of access to quality health services and protection from hardship, is another metric for which many have advocated as a potential means of improving #globalhealth security 7/ gh.bmj.com/content/bmjgh/…
But when you look at a consistent measure of performance none of our metrics have done well
This figure compares JEE readyscore w/cumulative reported, age-standardized #COVID19 deaths per 100k people in 50 days following date of first death in that country
No correlation 8/
The same is true of the Global Health Security Index
This figure shows overall GHS Index score, but we ran same comparison on more specific indicators from index, such as the “Rapid Response to and Mitigation of the Spread of an Epidemic”
Several countries that acted quickly to contain #COVID19, (eg South Korea & Taiwan) have high levels of universal health coverage. But same is true for many that have struggled in this pandemic, including Italy and United Kingdom 10/
One answer is that JEE, the Global Health Security Index, and measures of #UHC are not meant to predict health outcomes
They are important tools for identifying gaps in capacity and mobilizing financial and political support to fill those gaps 12/
Francis Fukuyama argues in @ForeignAffairs: capacity is 1 of 3 essential ingredients to nations’ success in #COVID19 pandemic—effective leadership and a government that citizens trust and listen to must also be in the mix
But in that formulation, you would expect capacity to be necessary, but not sufficient for success against #COVID19
At least as measured by JEE, GHSI, & UHC, that has not *so far* been case. Look at Vietnam 14/
My coauthors --Joe Dieleman, Sawyer Crosby @IHME_UW & @samckiernan -- and me are not first to observe this disconnect between capacity & #COVID19 performance
The contribution of this @ThinkGlobalHlth post is visualizing that disconnect with regard to #COVID19 deaths, extending analysis to #UHC, and accounting for national differences in population age-structure and the timing of the epidemic 17/
#COVID19 suggests as we scale up investments & create funds to help countries prepare for future epidemics, we also need to think more a/b how we measure preparedness & combine w/efforts to foster readiness & implementation 18/18 thinkglobalhealth.org/article/all-be…
• • •
Missing some Tweet in this thread? You can try to
force a refresh
The US has most outstanding, but that is misleading as President Biden just this week added 500m to US total pledged donation by 1.1B COVID vaccine doses
Maximizing potential benefit of vaccine donations depends on doses going where they can do the"most good" but there's no consensus on where that would be
This week's summit in Cornwall, UK should be the time when G7 leaders finally act on their promises to send surplus COVID-19 vaccine supplies to the many other countries where they remain scarce #G7UK
COVAX has been criticized by @ZekeEmanuel@GovindPersad & others for its population-based allocation scheme that does not direct most of its early vaccine supplies to the settings at the greatest risk of otherwise having high COVID-19 death rates 3/ nytimes.com/2021/05/24/opi…
Results published in Lancet indicate say this a/b 1 dose regimen
It will be interesting to see public response and distribution strategy for regimen w/lower efficacy than Pfizer/Moderna options & uncertainty about duration of protection thelancet.com/journals/lance…
Apparently, Oxford/AstraZeneca has not even filed a submission package with EMA yet. FDA decision isn't coming soon either.
This is such an important vaccine for global access and so much is strange about how its sponsors have pursued it reuters.com/article/us-hea…